BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21926962)

  • 1. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation.
    Breuer S; Preuner S; Fritsch G; Daxberger H; Koenig M; Poetschger U; Lawitschka A; Peters C; Mann G; Lion T; Matthes-Martin S
    Leukemia; 2012 Mar; 26(3):509-19. PubMed ID: 21926962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection.
    Dubovsky J; Daxberger H; Fritsch G; Printz D; Peters C; Matthes S; Gadner H; Lion T; Muller-Bérat N
    Leukemia; 1999 Dec; 13(12):2059, 2060-9. PubMed ID: 10602430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
    Schaap N; Schattenberg A; Mensink E; Preijers F; Hillegers M; Knops R; Pennings A; Boezeman J; Geurts van Kessel A; de Pauw B; de Witte T
    Leukemia; 2002 Jan; 16(1):13-21. PubMed ID: 11840258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
    Lawler M; McCann SR; Marsh JC; Ljungman P; Hows J; Vandenberghe E; O'Riordan J; Locasciulli A; Socié G; Kelly A; Schrezenmeier H; Marin P; Tichelli A; Passweg JR; Dickenson A; Ryan J; Bacigalupo A;
    Br J Haematol; 2009 Mar; 144(6):933-45. PubMed ID: 19183198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection.
    Matthes-Martin S; Lion T; Haas OA; Frommlet F; Daxberger H; König M; Printz D; Scharner D; Eichstill C; Peters C; Lawitschka A; Gadner H; Fritsch G
    Leukemia; 2003 Oct; 17(10):1934-42. PubMed ID: 14513041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.
    Mohamedbhai SG; Edwards N; Morris EC; Mackinnon S; Thomson KJ; Peggs KS
    Br J Haematol; 2012 Feb; 156(4):516-22. PubMed ID: 22171699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
    Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C
    Haematologica; 2005 Oct; 90(10):1405-14. PubMed ID: 16219578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of dynamic monitoring of cell chimerism following allogeneic hematopoietic stem cell transplantation].
    Jiang Y; Wan LP; Wang C; Yan SK; Gao YR; Jiang JL; Yang J; Cai Y; Bai HT; Wei DL; Xie KC
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):667-71. PubMed ID: 19176059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of allogeneic stem cell transplantation in children with non-malignant diseases.
    Willasch A; Hoelle W; Kreyenberg H; Niethammer D; Handgretinger R; Lang P; Beck JF; Klingebiel T; Bader P
    Haematologica; 2006 Jun; 91(6):788-94. PubMed ID: 16769581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
    Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders.
    Ozyurek E; Cowan MJ; Koerper MA; Baxter-Lowe LA; Dvorak CC; Horn BN
    Bone Marrow Transplant; 2008 Jul; 42(2):83-91. PubMed ID: 18391990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
    Mattsson J; Uzunel M; Remberger M; Hassan M
    Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
    Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplant monitoring of chimerism by lineage-specific analysis.
    Preuner S; Lion T
    Methods Mol Biol; 2014; 1109():271-91. PubMed ID: 24473788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT.
    Bühlmann L; Buser AS; Cantoni N; Gerull S; Tichelli A; Gratwohl A; Stern M
    Bone Marrow Transplant; 2011 Oct; 46(10):1357-62. PubMed ID: 21113185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
    Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
    Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival.
    Keil F; Prinz E; Moser K; Mannhalter C; Kalhs P; Worel N; Rabitsch W; Schulenburg A; Mitterbauer M; Greinix H
    Transplantation; 2003 Jul; 76(1):230-6. PubMed ID: 12865815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.